{"product_id":"elv-vrio-analysis","title":"Elevance Health Inc. (ELV): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eThis ready-made VRIO Analysis of Elevance Health, Inc. gives you a research-based breakdown of value, rarity, imitability, and organization, covering June 2026 strengths such as \u003cstrong\u003e45 million-plus\u003c\/strong\u003e member scale, brand trust, Carelon, CarelonRx, AI tools, and government-program expertise, so you can quickly see which resources create sustained versus temporary competitive advantage for essays, case studies, presentations, and business research.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Brand value and payer trust\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO factor\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eChapter relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e; \u003cstrong\u003e47 million+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRevenue scale and member base support retention and sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e; \u003cstrong\u003e47 million+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBroad national reach is hard to match\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrust and reputation build over decades\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eScale supports marketing and member-experience spending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e operating revenue in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e47 million+\u003c\/strong\u003e medical members\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e states\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e and \u003cstrong\u003e47 million+\u003c\/strong\u003e support retention, employer sales, and digital adoption.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e14\u003c\/strong\u003e states and \u003cstrong\u003e47 million+\u003c\/strong\u003e members make this trust position hard to match quickly.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e80+\u003c\/strong\u003e years of operating history make payer trust difficult to replicate.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e2024\u003c\/strong\u003e scale and \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e in revenue support leadership, marketing, and member-experience investment.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: National membership scale and distribution footprint\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e47 million+\u003c\/strong\u003e members across a \u003cstrong\u003e14\u003c\/strong\u003e-state core footprint.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e47 million+\u003c\/strong\u003e members spread fixed costs across a larger base and support larger claims and clinical data sets.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e47 million+\u003c\/strong\u003e members is elite scale in U.S. health insurance.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e14\u003c\/strong\u003e states, regulated network buildout, and member switching friction make replication difficult.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eSegment-led structure and centralized government-business operations support scale use.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life figure\u003c\/th\u003e\n\u003cth\u003eFootprint\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47 million+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMembers\u003c\/td\u003e\n\u003ctd\u003eCost spread\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47 million+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S. health insurance scale\u003c\/td\u003e\n\u003ctd\u003eElite scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStates\u003c\/td\u003e\n\u003ctd\u003eHard to copy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSegment leadership\u003c\/td\u003e\n\u003ctd\u003eScale capture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eNational footprint\u003c\/td\u003e\n\u003ctd\u003eSwitching friction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e47 million+\u003c\/strong\u003e members\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e states\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Integrated Carelon health-services platform\u003c\/h2\u003e\n\u003cp\u003eElevance Health’s Carelon platform supports a \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e revenue base in \u003cstrong\u003e2024\u003c\/strong\u003e and is harder to copy than a stand-alone insurer because it combines pharmacy, behavioral health, and care delivery under one structure. That makes the resource strategically valuable, moderately rare, and difficult to imitate quickly.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eCarelon helps Elevance capture more of the healthcare dollar through care management, services, and risk-based solutions. The scale matters: \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e in 2024 revenue gives the platform a large base for cross-selling and coordination.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe platform is not common. Elevance built Carelon in \u003cstrong\u003e2022\u003c\/strong\u003e, and the integrated model remains unusual among large insurers because it links multiple service lines inside one operating system.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCopying the model is slow and expensive. A rival would need acquisitions, integration, clinical infrastructure, and operating discipline across pharmacy, behavioral health, and care delivery, not just one product launch.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eElevance has organized around the platform through dedicated Carelon oversight and leadership restructuring. That supports execution across a business that sits next to a \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e company scale base.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Test\u003c\/th\u003e\n    \u003cth\u003eReal-Life Data\u003c\/th\u003e\n    \u003cth\u003eImplication\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e revenue in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eMore room to capture services revenue\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eCarelon launched in \u003cstrong\u003e2022\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eBroad integrated services model is uncommon\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003ePharmacy + behavioral health + care delivery\u003c\/td\u003e\n    \u003ctd\u003eHard to copy quickly\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eDedicated Carelon oversight\u003c\/td\u003e\n    \u003ctd\u003eBetter alignment and execution\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eValue, rarity, and organization align\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e 2024 revenue\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2022\u003c\/strong\u003e Carelon build-out\u003c\/li\u003e\n  \u003cli\u003ePharmacy\u003c\/li\u003e\n  \u003cli\u003eBehavioral health\u003c\/li\u003e\n  \u003cli\u003eCare delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: CarelonRx and pharmacy-benefit processing capability\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eCarelonRx supports recurring prescription claims and drug-cost management inside a company that reported \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e in 2024 revenue.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003ePBM processing is common in U.S. managed care, so the capability is not highly rare.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can build or buy similar systems, so the advantage is feasible to copy over time.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. CarelonRx is organized inside the Carelon platform and used across the enterprise.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eCarelonRx fit\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eRecurring script volume and drug-cost management\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003ePBM capability is widely available\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eBuild or buy over time\u003c\/td\u003e\n\u003ctd\u003eFeasible\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eOperationally embedded\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eValue: recurring prescription flow\u003c\/li\u003e\n\u003cli\u003eRarity: moderate\u003c\/li\u003e\n\u003cli\u003eInimitability: feasible over time\u003c\/li\u003e\n\u003cli\u003eOrganization: yes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Proprietary digital and AI assets\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eElevance Health, Inc.'s proprietary digital and AI assets reduce administrative cost, expand self-service, and lower prior-authorization denials and call burden. 2023 operating revenue was \u003cstrong\u003e$171.3 billion\u003c\/strong\u003e, so small efficiency gains can scale across a very large operating base.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe asset is rare at Elevance Health, Inc.'s scale because the tools are embedded across members and employees, not held as a stand-alone product.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartly imitable through vendor software and similar AI models.\u003c\/li\u003e\n\u003cli\u003eHard to copy because data integration, workflow embedding, and tuning take time and scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. Elevance Health, Inc. has the spending capacity, governance, and employee adoption needed to use these tools. 2023 net income was \u003cstrong\u003e$5.99 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life data point\u003c\/th\u003e\n\u003cth\u003eEffect on strategy\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$171.3 billion\u003c\/strong\u003e operating revenue in 2023\u003c\/td\u003e\n\u003ctd\u003eCreates room for administrative savings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eEmbedded across members and employees\u003c\/td\u003e\n\u003ctd\u003eHarder to match than a single digital tool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eData integration and workflow tuning\u003c\/td\u003e\n\u003ctd\u003eRaises copying cost and time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.99 billion\u003c\/strong\u003e net income in 2023\u003c\/td\u003e\n\u003ctd\u003eSupports continued technology use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Government programs expertise and public-sector relationships\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eMedicare and Medicaid were both created in \u003cstrong\u003e1965\u003c\/strong\u003e, and Elevance Health's government expertise matters because these businesses depend on pricing accuracy, eligibility rules, audits, and contract compliance.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThis capability is rare because few managed-care companies keep comparable depth across Medicare, Medicaid, and federal business lines, with \u003cstrong\u003e1\u003c\/strong\u003e dedicated Government Business president centralizing accountability.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIt is hard to copy because public-sector relationships, contracting know-how, and compliance systems take years to build and are tied to state and federal contract cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContracting discipline across multiple public programs.\u003c\/li\u003e\n\u003cli\u003eCompliance capability across changing rules and audits.\u003c\/li\u003e\n\u003cli\u003eRelationship depth built over time.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. The dedicated Government Business president shows the company is organized to capture this capability.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1965\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedicare and Medicaid are long-standing, regulated programs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDedicated Government Business leadership centralizes accountability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1965\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePublic-program complexity is long-running and hard to copy quickly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLeadership is structured to manage government business directly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Clinical care management and risk-based service delivery\n\u003c\/h2\u003e\n\u003cp\u003eElevance Health's clinical care management and risk-based service delivery is supported by \u003cstrong\u003e$176.8 billion\u003c\/strong\u003e in 2024 operating revenue. The advantage is real, but it is still temporary.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eImproves outcomes and controls utilization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e operating revenue in 2024\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eModerate to high\u003c\/td\u003e\n    \u003ctd\u003eExecution quality varies widely across the industry\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHard to match quickly\u003c\/td\u003e\n    \u003ctd\u003eAnalytics, provider workflows, and care teams\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eCarelon Health leadership and service expansion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003e2024\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$176.8 billion\u003c\/strong\u003e operating revenue in 2024\u003c\/li\u003e\n  \u003cli\u003eRisk-based care models\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate to high.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eAnalytics, provider workflows, and care teams.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eCarelon Health leadership and service expansion.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Financial strength and capital allocation capacity\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$171.3 billion\u003c\/strong\u003e in 2023 operating revenue and a \u003cstrong\u003e$1.63\u003c\/strong\u003e quarterly dividend support funding for AI, acquisitions, dividends, repurchases, and regulatory shocks; the edge is temporary.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$171.3 billion\u003c\/strong\u003e in 2023 operating revenue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$1.63\u003c\/strong\u003e per share quarterly dividend = \u003cstrong\u003e$6.52\u003c\/strong\u003e per share annualized.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO test\u003c\/td\u003e\n\u003ctd\u003eNumber\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e2023 operating revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$171.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eQuarterly dividend per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.63\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eAnnualized dividend per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.52\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; a \u003cstrong\u003e$171.3 billion\u003c\/strong\u003e insurer can generate cash at scale, but not all peers do so with the same consistency.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eRelatively easy for similarly scaled peers to approximate in principle.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$1.63\u003c\/strong\u003e per share quarterly dividends and \u003cstrong\u003e$6.52\u003c\/strong\u003e annualized dividends show capital deployment discipline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.63\u003c\/strong\u003e quarterly dividend per share\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.52\u003c\/strong\u003e annualized dividend per share\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElevance Health, Inc. - VRIO Analysis: Compliance, governance, and responsible-AI oversight\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary competitive advantage.\u003c\/strong\u003e The control structure supports compliance and responsible-AI oversight at scale, but it is not rare and can be copied.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHelps manage CMS sanctions, regulatory accruals, bias risk, and reputational exposure across \u003cstrong\u003e$171.3 billion\u003c\/strong\u003e in total operating revenue in 2023.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; many firms have compliance functions, but few integrate AI governance at scale.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStructure can be copied, but maturity, credibility, and process discipline take time.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBoard oversight and Responsible AI governance are in place.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eNumeric anchor\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eCMS sanctions, regulatory accruals, bias risk, reputational exposure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$171.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eCompliance functions are common; AI governance at scale is less common\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003ePolicies can be copied; execution discipline cannot\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eBoard oversight and Responsible AI governance\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e2023 total operating revenue: \u003cstrong\u003e$171.3 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCMS sanctions risk: material\u003c\/li\u003e\n\u003cli\u003eResponsible AI governance: in place\u003c\/li\u003e\n\u003cli\u003eCompetitive advantage: temporary\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516157386901,"sku":"elv-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/elv-vrio-analysis.png?v=1740169460","url":"https:\/\/dcf-model.com\/fr\/products\/elv-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}